The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

Video content above is prompted by the following:

What are the key takeaways from the most recent update of Axi-Cel in DLBCL (ZUMA-7: Westin et al. NEJM 2023) and Liso-Cel in DLBCL (TRANSFORM: Abramson et al. Blood 2023)?

• Do you think these studies support CAR T-cell therapy as the primary option for 2L treatment?
• Do you foresee CAR T-cell therapy becoming the primary 2L treatment option? If so, when do you see this occurring?

For transplant ineligible patients, what does efficacy and safety data for CAR T-cell therapy look like? Please briefly review and discuss key takeaways from ALYCANTE (Houot et al. Nature 2023) and PILOT (Sehgal et al. JCO 2022).